A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer

This study has been terminated.
Sponsor:
Information provided by:
Genentech
ClinicalTrials.gov Identifier:
NCT00114946
First received: June 20, 2005
Last updated: May 26, 2006
Last verified: May 2006
  Purpose

This is a randomized, open-label, active-control, multicenter trial comparing two oxaliplatin/Avastin-based treatment sequences as first-line therapy for metastatic colorectal cancer. The study is designed to compare the efficacy of these two treatment sequences with respect to progression free survival (PFS) and overall survival.


Condition Intervention Phase
Colorectal Cancer
Drug: Avastin
Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Randomized, Open-Label Trial Comparing Two Avastin (Bevacizumab)-Based Treatment Regimens for the First-Line Treatment of Metastatic Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Genentech:

Primary Outcome Measures:
  • To compare the efficacy, as measured by progression-free survival (PFS), of FOLFOX/Avastin followed by FOLFIRI/Avastin versus FOLFOX/Avastin followed by 5-FU/LV/Avastin as first-line therapy for previously untreated metastatic colorectal cancer.

Secondary Outcome Measures:
  • To evaluate the tolerability of sequential treatment in subjects and to evaluate the safety of an irinotecan/Avastin-based regimen versus a 5-FU/Avastin regimen for previously untreated metastatic colorectal cancer.

Estimated Enrollment: 800
Study Start Date: May 2005
Estimated Study Completion Date: December 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed Informed Consent Form
  • Metastatic or locally advanced and unresectable colorectal cancer
  • Measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)
  • Age >= 18 years
  • ECOG performance status of 0 or 1
  • Adequate hematologic, hepatic, and renal function at the time of study entry to begin prescribed study therapy, according to institutional guidelines
  • Use of an effective form of contraception during the study (for subjects of childbearing potential and their partners)

Exclusion Criteria:

  • Prior treatment with Avastin
  • Hypersensitivity to any of the study drugs or ingredients
  • Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin cancer study
  • History of any other malignancy (except squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum that has been effectively treated) unless in complete remission and off all therapy for that malignancy for at least 5 years
  • Known brain or central nervous system metastases
  • Prior treatment for advanced or metastatic colorectal cancer
  • Prior treatment with an anti-angiogenesis agent, in either the adjuvant or metastatic setting
  • Concurrent use of investigational anti-neoplastic agents (including up to 4 weeks prior to enrollment)
  • Medical or psychiatric disorders that would interfere with informed consent or compliance, or would render the subject at high risk for participation in this study and its follow-up procedures
  • Active infection requiring antibiotics on Day 1
  • New York Heart Association (NYHA) Grade II or greater CHF
  • Evidence of bleeding diathesis or coagulopathy
  • Grade > 1 peripheral neuropathy (as defined by the NCI CTCAE, v3.0)
  • Lack of physical integrity of the upper gastrointestinal tract or history of malabsorption syndrome
  • Blood pressure > 150/100 mmHg
  • Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Day 1; anticipation of need for a major surgical procedure during the course of the study
  • Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 1
  • Urine protein:creatinine ratio >= 1.0 at screening
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1
  • Serious, non-healing wound, ulcer, or bone fracture
  • History of myocardial infarction within 6 months prior to Day 1
  • Unstable angina
  • Clinically significant peripheral vascular disease
  • History of stroke within 6 months prior to Day 1
  • Pregnancy (positive pregnancy test) or lactation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00114946

Sponsors and Collaborators
Genentech
Investigators
Study Director: Mary Sugrue, M.D. Genentech
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00114946     History of Changes
Other Study ID Numbers: AVF3430n
Study First Received: June 20, 2005
Last Updated: May 26, 2006
Health Authority: United States: Institutional Review Board

Keywords provided by Genentech:
Metastatic Colorectal Cancer OASIS

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 15, 2014